Bifogade filer
Kurs
-5,71%
Likviditet
113 MDKK
Kalender
Tid* | ||
2025-11-06 | 07:00 | Kvartalsrapport 2025-Q3 |
2025-08-14 | 07:00 | Kvartalsrapport 2025-Q2 |
2025-05-08 | 07:00 | Kvartalsrapport 2025-Q1 |
2025-02-20 | 18:00 | Bokslutskommuniké 2024 |
2024-11-07 | - | Kvartalsrapport 2024-Q3 |
2024-08-15 | - | Kvartalsrapport 2024-Q2 |
2024-05-16 | - | Kvartalsrapport 2024-Q1 |
2024-03-21 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2024-03-20 | - | Årsstämma |
2024-02-27 | - | Bokslutskommuniké 2023 |
2023-11-09 | - | Kvartalsrapport 2023-Q3 |
2023-08-17 | - | Kvartalsrapport 2023-Q2 |
2023-05-11 | - | Kvartalsrapport 2023-Q1 |
2023-03-30 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2023-03-29 | - | Årsstämma |
2023-03-02 | - | Bokslutskommuniké 2022 |
2022-11-10 | - | Kvartalsrapport 2022-Q3 |
2022-08-11 | - | Kvartalsrapport 2022-Q2 |
2022-05-12 | - | Kvartalsrapport 2022-Q1 |
2022-05-09 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2022-04-06 | - | Årsstämma |
2022-03-10 | - | Bokslutskommuniké 2021 |
2021-11-11 | - | Kvartalsrapport 2021-Q3 |
2021-08-12 | - | Kvartalsrapport 2021-Q2 |
2021-05-12 | - | Kvartalsrapport 2021-Q1 |
2021-04-16 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2021-04-15 | - | Årsstämma |
2021-03-11 | - | Bokslutskommuniké 2020 |
2020-11-12 | - | Kvartalsrapport 2020-Q3 |
2020-08-13 | - | Kvartalsrapport 2020-Q2 |
2020-05-14 | - | Kvartalsrapport 2020-Q1 |
2020-04-03 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2020-04-02 | - | Årsstämma |
2020-03-12 | - | Bokslutskommuniké 2019 |
2019-11-14 | - | Kvartalsrapport 2019-Q3 |
2019-08-15 | - | Kvartalsrapport 2019-Q2 |
2019-05-16 | - | Kvartalsrapport 2019-Q1 |
2019-04-05 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2019-04-04 | - | Årsstämma |
2019-03-07 | - | Bokslutskommuniké 2018 |
2018-11-15 | - | Kvartalsrapport 2018-Q3 |
2018-08-16 | - | Kvartalsrapport 2018-Q2 |
2018-05-16 | - | Kvartalsrapport 2018-Q1 |
2018-04-20 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2018-04-19 | - | Årsstämma |
2018-03-07 | - | Bokslutskommuniké 2017 |
2017-11-08 | - | Kvartalsrapport 2017-Q3 |
2017-08-24 | - | Kvartalsrapport 2017-Q2 |
2017-05-17 | - | Kvartalsrapport 2017-Q1 |
2017-04-06 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2017-04-05 | - | Årsstämma |
2017-03-15 | - | Bokslutskommuniké 2016 |
2016-11-09 | - | Kvartalsrapport 2016-Q3 |
2016-08-25 | - | Kvartalsrapport 2016-Q2 |
2016-05-18 | - | Kvartalsrapport 2016-Q1 |
2016-04-20 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2016-04-19 | - | Årsstämma |
2016-03-16 | - | Bokslutskommuniké 2015 |
2015-11-05 | - | Kvartalsrapport 2015-Q3 |
2015-08-28 | - | Kvartalsrapport 2015-Q2 |
2015-05-22 | - | Kvartalsrapport 2015-Q1 |
2015-04-22 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2015-04-21 | - | Årsstämma |
2015-03-12 | - | Bokslutskommuniké 2014 |
2014-11-07 | - | Kvartalsrapport 2014-Q3 |
2014-08-21 | - | Kvartalsrapport 2014-Q2 |
2014-05-06 | - | Kapitalmarknadsdag 2014 |
2014-04-29 | - | Årsstämma |
2014-04-29 | - | Kvartalsrapport 2014-Q1 |
2014-03-21 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2014-03-20 | - | Bokslutskommuniké 2013 |
2013-11-15 | - | Kvartalsrapport 2013-Q3 |
2013-08-29 | - | Kvartalsrapport 2013-Q2 |
2013-05-15 | - | Kvartalsrapport 2013-Q1 |
2013-04-30 | - | Årsstämma |
2013-04-30 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2013-03-14 | - | Bokslutskommuniké 2012 |
2012-11-29 | - | Kapitalmarknadsdag 2012 |
2012-04-26 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2012-04-25 | - | Årsstämma |
2011-11-17 | - | Kvartalsrapport 2011-Q3 |
2011-10-25 | - | Kapitalmarknadsdag 2011 |
2011-08-18 | - | Kvartalsrapport 2011-Q2 |
2011-05-12 | - | Kvartalsrapport 2011-Q1 |
2011-04-29 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2011-04-28 | - | Årsstämma |
Beskrivning
Land | Danmark |
---|---|
Lista | Large Cap Copenhagen |
Sektor | Hälsovård |
Industri | Bioteknik |
Company announcement – No. 17 / 2023
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Copenhagen, Denmark, April 25, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.
Please see the attached file(s).
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development and partnerships with a number of blue-chip pharma companies as well as commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.
Forward-Looking Statement
The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly.
Contact:
Anna Krassowska, PhD Vice President, Investor Relations & Corporate Communications Zealand Pharma Email: ank@zealandpharma.com |